A series of 2-(p-substituted-benzyl)-5-[[4-(p-chloro/fl uoro-phenyl)piperazin-1-yl]ace tamido] -benzoxazoles were synthesized in need of new compounds for the fi ght against microbial pathogens. Their structures were elucidated by spectral techniques. These new derivatives, along with previously synthesized 2-(p-substituted-benzyl)-5-substituted-benzoxazoles, were evaluated for their antibacterial and antifungal activities against standard strains and drugresistant isolates in comparison with ampicillin, gentamicin sulfate, ofl oxacin, vancomycin, fl uconazole, and amphotericin B trihydrate. The minimum inhibitory concentration (MIC) of each compound was determined by a two-fold serial dilution technique. The compounds were found to possess a broad spectrum of antimicrobial activities with MIC values of 32 -256 μg/ml. Although standard drugs were more active against the pathogenes employed in this study, the activities of the new benzoxazoles and reference drugs against drug-resistant isolates of the microorganisms were largely similar. 
Introduction
The fi ght against bacterial infections has resulted in the development of a wide variety of antibiotics. After years of misuse of antibiotics, bacteria have become antibiotic-resistant, resulting in a potential global health crisis. Infectious diseases due to Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VREF), and penicillin-resistant Streptococcus pneumoniae (PRSP) are the leading causes of morbidity and mortality today (Moustafa et al., 2004) . Besides, during the past 20 years an increase in invasive fungal infections, particularly in immunosuppressed patients, has been observed which are now considered to be causes of morbidity and mortality as well. Therefore, there is still need for new antifungal and antibacterial agents (Andriole, 1999) . Benzoxazoles are the structural isosteres of natural nucleotides and interact easily with the biopolymers so that they constitute an important class of heterocyclic compounds with antimicrobial and antibiotic activity (Prudhomme et al., 1986; Sarma et al., 2003; Haansuu et al., 2001; Temiz-Arpaci et al., 2002 , 2005 Yildiz-Oren et al., 2004; Tekiner-Gulbas et al., 2007) . The benzoxazole derivative calcimycin ( Fig. 1) is a carboxylic polyether antibiotic from a strain of Streptomyces chartreusis (NRRL 3882) . It was found to be very active against Gram-positive bacteria including some Bacillus and Micrococcus strains (Prudhomme et al., 1986) .
In the last seven years we have described the synthesis of different derivatives of some 2,5-disub stituted benzoxazoles and their in vitro antimicrobial activity against some Gram-positive and Gram-negative bacteria and the fungus Candida albicans (Temiz-Arpaci et al., 2005 Oksuzoglu et al., 2007 Oksuzoglu et al., , 2008 Arisoy et al., 2008) . In the present study, a new series of 2-(p-sub-
3 -12, has been synthesized as target compounds and evaluated for their antibacterial and antifungal activities, along with previously synthesized benzoxazole derivatives, against standard strains and drug-resistant isolates in comparison with several reference drugs. Furthermore, structure-activity relationships (SAR) are discussed. 
Synthesis and Antimicrobial Activity of Novel Benzoxazoles

Results and Discussion
We aimed at enhancing the antimicrobial activity of 2,5-disubstituted benzoxazoles by expanding the substituent at the C-5 position. To this end, some new 2-(p-substituted-benzyl)-5-[[4-(pchloro/fl uoro-phenyl)piperazin-1-yl]acetamido]-benzoxazoles, 3 -12, were synthesized. The synthetic route for preparation of the target compounds is shown in Scheme 1. First the 5-amino-2-(p-substituted-benzyl)-benzoxazoles 1a -1e were obtained by heating appropriate acids with 2,4-diaminophenol in polyphosphoric acid (PPA). The amides 2a -2e were then obtained through the reaction of 5-amino-2-(p-substituted-benzyl)-ben zo xazoles with chlo ro acetyl chloride. In the last step the newly synthesized compounds 3 -12 were prepared from the amides by treating them with 4-substituted piperazine derivatives. Their structures were elucidated by mass and NMR spectroscopy, respectively, and their purity was analysed through elemental analysis (Table I) . The compounds were also evaluated for their antimicrobial activity along with previously synthesized benzoxazole derivatives (Table II) .
Compounds 3 -12 had same but low antibacterial activity against the bacteria S. aureus and E. faecalis with minimum inhibitory concentration (MIC) values between 128 -256 μg/ml which are higher than those of the standards ampicillin, gentamicin, ofl oxacin, and vancomycin. Nevertheless, these compounds had enhanced activity against the drugresistant isolates of these bacteria, in the range of a MIC value of 64 μg/ml of ampicillin against MRSA (Staphylococcus aureus isolate resistant to methicillin), except for compound 8 which was as potent as gentamicin and vancomycin against the isolate of E. faecalis with a MIC value of 32 μg/ml. The new benzoxazole derivatives possessed low antibacterial activity against B. subtillis and its drugresistant isolate with MIC values of 128 μg/ml.
Compounds 3 -12 provided moderate activity against P. aeruginosa and its drug-resistant isolate with MIC values of 64 μg/ml. They had the same activity like ofl oxacin against the drug-resistant isolate of P. aeruginosa. All derivatives 3 -32 possessed low activity against the standard strains of E. coli and K. pneumoniae in comparison with the standard drugs and, in general, the activities of the previously synthesized derivatives 13 -32 
12.
Compound
Formula Calculated Found J m = 1.6), 9.92 (H, s) 34. 07, 48.55, 53.21, 62.32, 110.91, 110.97, 117.51, 118.00, 122.96, 129.28, 131.68, 132.49, 134.84, 136.14, 141.61, 147.26, 150.48, 166.37, 168.81 495 (100) 497 (70) 499 (15 30, 34.49, 49.53, 53.39, 62.36, 110.91, 115.81, 116.03, 117.76, 117.83, 117.88, 129.54, 129.89, 132.75, 136.09, 136.85, 141.71, 147.29, 148.60, 155.49, 157.84, 166.87, 168.82 459 (100 H 5.05, N 11.70 C 65.29, H 4.71, N 11.53 were higher than those of the new benzoxazoles. The activities of all compounds against the isolates of these bacteria were as high as those of ampicillin and better than those of gentamicin. The comparison of the activities of the new benzoxazoles with those of the antifungal drugs fl uconazole and amphothericin B showed that the newly synthesized compounds were less inhibitory against C. albicans and C. krusei with MIC values between 64 μg/ml and 256 μg/ml. It can be concluded that different substituents at the C-5 position of the 2-(p-substitutedbenzyl)-benzoxazole nucleus provided similar antimicrobial activity. The activities of standard drugs against standard strains were higher than those of the benzoxazole derivatives, whereas in most cases the MIC values of standard drugs against the isolates of the bacteria were quite similar to those of the benzoxazoles.
Experimental
Materials and methods
Chemicals and solvents were purchased from Sigma-Aldrich (Taufkirchen, Germany) and Fisher Scientifi c (Pittsburgh, PA, USA) and were used without further purifi cation. Silica gel HF 254 chromatoplates (0.3 mm) were used for thin layer chromatography (TLC), and the mobile phase was chloroform/methanol (10:0.5, v/v) for compounds 3 -12. Melting points (M.p.) were recorded on a Stuart Scientifi c SMP 1 (Bibby Scientifi c Limited, Staffordshire, UK) instrument and are uncorrected. NMR spectra were recorded on a Varian (Palo Alto, CA, USA) Mercury 400 MHz NMR spectrometer in CDCl 3 or dimethylsulfoxide (DMSOd 6 ); tetramethylsilane (TMS) was used as an internal standard. The mass spectra were recorded on a Waters (Milford, MA, USA) ZQ Micromass LC-MS spectrometer using the ESI(+) method. 
, not determined (microbiological assays were not performed due to following reasons: P. aeruginosa is naturally resistant to ampicillin; Gram-negative bacteria employed in the study are naturally resistant to vancomycin; vancomycin is not used in the therapy against B. subtilis; antibacterial drugs were not assayed against fungi; antifungal drugs were not assayed against bacteria 
General procedure for the preparation of 5-amino-2-(p-substituted-benzyl)-benzoxazoles (1a -1e)
The 5-amino-2-(p-substituted-benzyl)-benzoxazoles were synthesized by heating 0.02 mol 2,4-diaminophenol hydrochloride with 0.02 mol p-substituted phenyl acetic acid in 25 g polyphosphoric acid (PPA) and stirring for 1 -2 h. At the end of the reaction period, the residue was poured into an ice/water mixture, and the solution was neutralized with 10% NaOH. The resulting precipitate was fi ltered, washed with distilled water, dissolved in boiling ethanol with 0.2 g charcoal, and fi ltered off. Then distilled water was added slowly to the fi ltrate in order to stimulate crystallization. The crude compounds 1a -1e were obtained by fi ltering and drying the crystalline material (Yildiz-Oren et al., 2004; Oksuzoglu et al., 2007 Oksuzoglu et al., , 2008 TemizArpaci et al., 2008; Arisoy et al., 2008) .
General procedure for the preparation of 5-(2-chloroacetamido)-2-(p-substituted-benzyl)-benzoxazoles (2a -2e)
Chloroacetyl chloride (0.02 mol) was added over a period of 1 h to a stirred, ice-cooled mixture of 5-amino-2-(p-substituted-benzyl)-benzoxazole (0.02 mol), sodium bicarbonate (0.02 mol), diethyl ether (40 ml), and water (20 ml). The mixture was continuously stirred overnight at room temperature and fi ltered. The precipitate was washed with water, 2 M HCl, and water, respectively, and the crude product was obtained by drying needles in vacuo (Arisoy et al., 2008) .
General procedure for the preparation of 2-(p-substituted-benzyl)-5-[[4-(p-chloro/fl uorophenyl) 
0.002 mol 5-(2-chloroacetamido)-2-(p-substituted-benzyl)-benzoxazole were added to 0.002 mol N-(p-chloro/fl uoro-phenyl)piperazine and 0.006 mol triethylamine (TEA) solution in 3.5 ml N,N-dimethylformamide (DMF). The mixture was stirred at room temperature for 24 h. At the end of the reaction time, 5 ml toluene were added, and the reaction medium was evaporated under reduced pressure. The residue was dissolved in chloroform and washed three times with 5% NaOH and then once with distilled water. The solution was dried over anhydrous sodium sulfate, fi ltered, and evaporated under reduced pressure. The residue was dissolved in ethyl acetate and precipitated by adding n-hexane. If necessary, recrystallization was performed. Crystalline material was dried in vacuo. All the compounds 3 -12 were prepared as original products. Their structures were supported by spectral data. The mass and 1 H NMR spectra, respectively, and the results of the elemental analyses agree with those of the proposed structures. 13 C NMR spectra were obtained only for compounds 3, 6, 8, 11. Physical and spectral data of the compounds are reported in Table I .
Microbiological assays
For microbiological assays, ampicillin, gentamicin sulfate, ofl oxacin, vancomycin, fl uconazole, and amphotericin B trihydrate were dissolved in appropriate solvents recommended by the Clinical and Laboratory Standards Institute (CLSI) guidelines (CLSI, 2006 (CLSI, , 2008 . Stock solutions of the test compounds were prepared in DMSO.
Bacterial susceptibility testing was performed according to the guidelines of CLSI M100-S18 (CLSI, 2008) . MHB was added to each well of the microplates. The bacterial suspensions used for inoculation were prepared at 10 5 CFU/ml by diluting fresh cultures at McFarland 0.5 density (10 7 CFU/ml). Two-fold diluted solutions of the compounds were inoculated with bacterial suspensions of 10 5 CFU/ml (10 μl inoculum per well to give 10 4 CFU/ml bacteria in the wells), and the microplates were incubated overnight at 37 °C.
Fungal susceptibility testing was performed according to the guidelines of CLSI M27-A3 (CLSI, 2006) . RPMI-1640 medium with L-glutamine buffered to pH 7 with MOPS was added to each well of the microplates. The colonies were suspended in sterile saline, and the resulting suspension was adjusted to McFarland 0.5 density (10 6 CFU/ml). A working suspension was prepared by an 1:100 dilution followed by an 1:20 dilution of the stock suspension. 10 μl of this suspension at 10 3 CFU/ ml were added to the two-fold diluted solution of the compounds, and microplates were incubated for 24 -48 h at 35 °C.
After incubation, the lowest concentration of the compounds that completely inhibited visible growth was determined and reported as minimum inhibitory concentration (MIC). Control wells contained all components, except the tested compounds, and all experiments were done in triplicate.
